HEP-NET OPINION ABOUT THE MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN PAKISTAN IN THE ERA OF AVAILABLE DIRECT ACTING ANTIVIRALS

Main Article Content

Javed Iqbal Farooqi
Altaf Alam
Zaigham Abbas
Altaf Baqir Naqvi
Bader Faiyaz Zuberi
Arif Amir Nawaz
Anwaar A Khan
Zahid Yaseen Hashmi
Asad Ali Chaudhry
Zahid Azam
Muhammed Salih
Bushra Ali
Masood Siddiq
Lubna Kamani
Zeeshan Ali
Aftab Haider
Shahid Majid

Abstract

In Pakistan, we have 4.9% prevalence of HCV in general population, with 79% genotype 3. Recently Sofosbuvir has been made available at compassionate price in Pakistan. Management of chronic hepatitis C includes counseling of HCV patients, their proper assessment to select those who need antiviral therapy, initiation of appropriate antiviral agents & duration of therapy, along-with careful monitoring for safety and efficacy. Hepatic status as well as pre-vious history of HCV therapy needs to be taken in the consideration before starting antiviral therapy. Other factors include co-morbid conditions like obesity, DM, NASH, etc. Treatment of special populations like liver transplant pa-tients, patients with HBV co-infection, chronic kidney disease and hemoglobinopathies need special considerations when initiating HCV therapy.

Article Details

How to Cite
1.
Farooqi JI, Alam A, Abbas Z, Naqvi AB, Zuberi BF, Nawaz AA, Khan AA, Hashmi ZY, Chaudhry AA, Azam Z, Salih M, Ali B, Siddiq M, Kamani L, Ali Z, Haider A, Majid S. HEP-NET OPINION ABOUT THE MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN PAKISTAN IN THE ERA OF AVAILABLE DIRECT ACTING ANTIVIRALS. J Postgrad Med Inst [Internet]. 2016 Feb. 6 [cited 2022 Dec. 7];30(1). Available from: https://jpmi.org.pk/index.php/jpmi/article/view/1889
Section
Special Article

Most read articles by the same author(s)

1 2 > >>